SCHEMBL497708

SCHEMBL497708

OCc1c(C2CC2)nnn1-c1ccccc1OC(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.41
HCAR1 Q9BXC0 3/20 0.40
KCNN4 O15554 2/20 0.39
NOTUM Q6P988 1/20 0.34
P2RX7 Q99572 2/20 0.34
CHRM4 P08173 2/20 0.33
LGALS3 P17931 1/20 0.33
CYP2C9 P11712 1/20 0.33
EPHX2 P34913 1/20 0.33
CYP2J2 P51589 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2D6 P10635 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
KCNH2 Q12809 1/20 0.32
CYP1A2 P05177 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
JAK3 P52333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17843232 0.88 HCAR1 (0.40) SCN9AHCAR1KCNN4P2RX7CHRM4
SCHEMBL20749504 0.83 HCAR1 (0.37) SCN9AHCAR1KCNN4P2RX7CYP2C9
SCHEMBL498054 0.80 KCNN4 (0.42) SCN9AHCAR1KCNN4NOTUMP2RX7
SCHEMBL2770345 0.79 HCAR1 (0.40) SCN9AHCAR1KCNN4P2RX7CHRM4
SCHEMBL497828 0.78 SLC5A1 (0.42) SCN9AHCAR1KCNN4P2RX7ALDH1A1
SCHEMBL497639 0.77 KCNN4 (0.40) SCN9AHCAR1KCNN4NOTUMP2RX7
SCHEMBL27740962 0.77 NR1H4 (0.36) SCN9AKCNN4JAK2JAK1TYK2
SCHEMBL3159951 0.74 NR1H4 (0.46) SCN9AKCNH2
SCHEMBL498171 0.68 NR1H4 (0.44) NOTUMALDH1A1CYP1A2
SCHEMBL2775248 0.68 KCNK3 (0.37) SCN9AHCAR1KCNN4P2RX7CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107108595-B Novel FXR (NR1H4) modulating compounds 吉利德科学公司 2021-04-06 CN disclosed
EP-3233831-B1 NOVEL FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2019-02-20 EP disclosed
EP-3233831-B1 NOVEL FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2019-02-20 EP disclosed
EP-3233831-A1 NOVEL FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2017-10-25 EP disclosed
WO-2016096116-A1 NOVEL FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2016-06-23 WO disclosed
WO-2016096116-A1 NOVEL FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2016-06-23 WO disclosed
US-8106077-B2 Compounds and methods for modulating FXR ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
EP-2029558-B1 COMPOUNDS AND METHODS FOR MODULATING FXR LILLY CO ELI (US) 2010-03-10 EP disclosed
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 SCN9A 3726/4885HCAR1 289/4885KCNN4 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.